BioSpace News Archive

BioSpace spoke with two professionals who have made the switch from tech roles to biotech to find out the benefits, challenges and tips for a smooth transition.

In an open letter published Monday, more than 480 biopharma industry leaders expressed their support for the FDA after a Texas federal judge ruled to hold the approval of the abortion pill mifepristone.

Karuna Therapeutics’ KarXT and Acadia Pharmaceuticals’ pimavanserin are sparking hope that a treatment for the negative symptoms of schizophrenia could be on the horizon.

Data from two mid-stage studies show HI-Bio’s investigational therapy felzartamab lowers pathogenic antibody titers in patients with primary membranous nephropathy (PMN).

OnCusp Therapeutics today announced that the preclinical data on its lead program CUSP06 will be presented during the American Association for Cancer Research Meeting.

Quadriga BioSciences today announced the dosing of the first subject in a Phase 2 study evaluating QBS72S for the treatment of brain metastases of breast cancers.

Mission Bio, Inc. today announced that it has entered into an agreement with Fulgent Genetics (NASDAQ: FLGT), a technology-based company with well-established clinical diagnostic and therapeutic development businesses.

Boundless Bio today announced that its President and Chief Executive Officer, Zachary Hornby, will present at the Stifel 2023 Virtual Targeted Oncology Days event which will take place virtually.

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer (CFO), Cameron Trenor, M.D., as Vice President and Head of Translational Medicine, and Anjali Kumar, Ph.D., as Vice President, Head of Business Development.

Sonoma Biotherapeutics, Inc. today announced the formation of its scientific advisory board.